Market Moves
Founders Fund and the OpenAI Startup Fund co-lead Coherence Neuro's US$45 million round
Coherence Neuro, which is developing a brain implant to monitor and treat brain tumours, announced a US$45 million round, which it calls its Series A, on 21 October 2026, co-led by Founders Fund and the OpenAI Startup Fund. The money is for its first long-term human trial in glioblastoma, an application for FDA Breakthrough Device designation and preclinical work in pancreatic cancer. Chief executive Ben Woodington says OpenAI will not have access to any brain or health data the company generates.